Arteriovenous (AV) fistula access dysfunction causes significant morbidity with resultant increased healthcare spending, approaching $3 billion annually for Medicare. Recently, 12-month data from the IN.PACT AV Access study has shown a decreased number of reinterventions after drug-coated balloon (DCB) angioplasty when compared with standard percutaneous transluminal angioplasty (PTA). Based on these data, our objective was to explore the potential economic consequences of IN.PACT DCB usage in the U.S. healthcare system.
